Yara International ASA (YAR)

The panel's take

Verdict: WAIT · Conviction: MEDIUM · Last price: NOK 459.0 (as of 2026-07-16)

Yara enters this panel with no bullish voices and two outright bearish ones — not because the business is troubled, but because the price doesn't yet reflect normalized, through-the-cycle earnings. The stock's run to an all-time high near NOK 599 was driven largely by a geopolitical urea-price spike; that spike has partly unwound, and the same disruption is now pushing Yara's natural-gas input costs higher into tomorrow's earnings print. The balance sheet is genuinely strong and management's capital allocation is disciplined — but with a dated catalyst (Q2 results) and a value-lens fair-value zone still meaningfully below today's price, the panel's synthesis is WAIT.

Key levels

Key support sits at NOK 437-440, a Fibonacci/prior-pullback confluence, but this is a shallow technical shelf, not a value-confirmed zone. A deeper historical accumulation zone sits at NOK 340-345 — the prior consolidation range that launched the entire 2025 advance — and it is here, not at the shallower shelf above it, that the panel's own valuation math (see below) starts to agree with the chart. The analyst consensus target sits at NOK 505, modestly above today's price.

Where the chart and the valuation models agree: the panel's two normalized-earnings estimates — one from the value lens's conservative multiple, one from the intrinsic-value model's discounted cash flow — both land close to the NOK 340-380 range. That's the same neighborhood as the deeper historical accumulation zone above, not the shallower support just below today's price. When a technical base and an independent valuation estimate converge like this, it's a stronger signal than either alone — though still a zone to watch, not a level to chase.

What legendary investors think

We ran Yara past a panel of six legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Is this a disciplined, financially strong operator caught in an ordinary post-spike pullback toward a genuine value zone — or a well-run cyclical business still priced for a peak that's already fading, with a binary earnings event about to test which is true?

The numbers

Metric	Value
Price / Market cap	NOK 459.0 / ~NOK 117B
P/E (TTM / fwd)	~8.7x / ~10.7x (forward above trailing — the market is pricing some normalization)
ROE	~14.6% (ROIC 10.7%, above the company's own 10% through-cycle target)
Operating margin	~18% EBITDA margin (FY2025)
Dividend yield	~4.8% (NOK 22/share, FY2025)
Debt / equity	Net debt/EBITDA 1.0x pre-acquisition (1.7x pro forma) / net debt-to-equity 0.33x — both inside policy targets
Free cash flow	Positive and improving; medium-term target of >$600M cumulative FCF expansion, 2024-2030

Figures as of Q1 2026 (reported Apr 24, 2026) and FY2025; sourced from Yara investor relations, GuruFocus, stockanalysis.com, Jefferies research notes. Multiple third-party aggregators show wide dispersion on P/E/ROE figures for this name due to a 2024-2025 earnings base effect (near-zero to peak in one year) — the figures above are reconciled to company-reported net income rather than taken from a single source. Next print: July 17, 2026 (Q2 2026) — one day after this analysis.

The bottom line

Yara is a financially disciplined, well-run nitrogen producer whose stock ran hard on a geopolitical supply shock and has since given back roughly a quarter of that move. The panel finds no bullish conviction and two explicitly bearish views, but the underlying disagreement isn't about whether Yara is a sound business — it clearly is, on the balance sheet and management-quality dimensions. It's about price: two independent value estimates land meaningfully below today's level, and the chart's highest-quality historical accumulation zone sits in that same lower neighborhood, not at the shallower support just beneath the current price. With a binary earnings catalyst landing the day after this analysis and no lens finding a genuine discount at NOK 459, the synthesis is patience rather than either enthusiasm or alarm — a business worth continuing to watch, at a price the panel isn't yet ready to call cheap.

The panel's take

Verdict: WAIT · Conviction: MEDIUM · Last price: NOK 451.3 (as of 2026-07-18)

What changed since 2026-07-16:

• Price: NOK 459.0 → 451.3 (-1.7%) — a Q2 print that landed without a gap-down or a volume spike, drifting price modestly lower rather than jolting it either way.
• Panel: 0 of 6 → 0 of 6 still Bullish (unchanged) — but the Intrinsic-Value Modeler and the Macro Opportunist both moved from Bearish to Neutral, leaving all six lenses Neutral for the first time in this series.
• Trigger: the panel is watching for either a decisive move toward the NOK 340-345 historical accumulation zone or a reclaim of NOK 500+.
• Verdict: WAIT (unchanged)

The read is unchanged because nothing about the underlying valuation math moved: the panel's normalized-earnings and DCF estimates still converge in the NOK 330-380 range, meaningfully below today's price, and the weekly trend remains in its bearish zone with the reclaim level near NOK 557 unreached. A muted earnings reaction removes a source of near-term uncertainty but doesn't manufacture a discount — the panel needs either price to fall toward its value estimate or the trend to reclaim NOK 500+ before the calculus changes.

Key levels

Key support sits at NOK 437-440, a shallow technical shelf not yet confirmed by valuation, with a deeper historical accumulation zone at NOK 340-345 where the panel's normalized-earnings and DCF estimates converge. Key resistance begins near NOK 555-559 — the weekly trend-reclaim level — and extends up toward NOK 596. The analyst consensus target sits at NOK 505, modestly above today's price.

Where the chart and the valuation models still agree: the panel's normalized-earnings estimate and the intrinsic-value model's discounted cash flow continue to land close to the NOK 340-380 range — the same neighborhood as the deeper historical accumulation zone, not the shallower shelf just below today's price. That convergence is unchanged from the prior read; what's new this week is that the Q2 print passed without disturbing either estimate.

What legendary investors think

We ran Yara past a panel of six legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Is Yara's post-earnings calm a sign the stock has found its level and is now mostly a function of time, or does the still-bearish weekly trend and the ~25% gap to the panel's valuation-confirmed zone mean the more favorable price still hasn't arrived?

The numbers

Metric	Value
Price / Market cap	NOK 451.3 / ~NOK 115B
P/E (TTM / fwd)	~8.6x / ~10.7x (forward above trailing — the market is still pricing some normalization)
ROE	~14.6% (ROIC ~10.7%, above the company's own 10% through-cycle target)
Operating margin	~18% EBITDA margin (FY2025)
Dividend yield	~4.9%
Debt / equity	Net debt/EBITDA ~1.0x pre-acquisition (~1.7x pro forma) / net debt-to-equity ~0.33x — both inside policy targets
Free cash flow	Positive and improving; medium-term target of >$600M cumulative FCF expansion, 2024-2030

Figures as of Q2 2026 (reported Jul 17, 2026) and FY2025; sourced from Yara investor relations, GuruFocus, stockanalysis.com, Jefferies research notes. Multiple third-party aggregators show wide dispersion on P/E/ROE figures for this name due to a prior-year earnings base effect — the figures above are reconciled to company-reported net income rather than taken from a single source. Next print: Q3 2026 results, expected October 2026.

The bottom line

With Q3 2026 results not due until October, the next scheduled catalyst is thin — the near-term case now rests on price action rather than a fresh data point. A weekly close back above the NOK 555-559 reclaim level would be the first technical signal the panel would treat as evidence the trend itself has turned, independent of valuation. Conversely, a slide into the NOK 340-345 accumulation zone would bring price into the range where the panel's normalized-earnings and DCF estimates already sit, at which point the low-multiple case gains valuation backing rather than resting on the multiple alone. Absent either move, expect the panel to stay parked at Neutral across the board into the next print.

The panel's take

Verdict: WAIT · Conviction: MEDIUM · Last price: NOK 456.1 (as of 2026-07-25)

What changed since 2026-07-18:

• Price: NOK 451.3 → NOK 456.1 (+1.06%) — essentially flat. The two most recent weekly closes are identical, sitting just under the 468-472 supply shelf rather than pushing through it.
• Panel: 6 of 6 still Neutral (unchanged) — no lens moved to Bullish or Bearish. The Moat Compounder leaned harder on five straight weeks of softer urea/UAN prices as a reason to keep waiting, while the Margin-of-Safety Hunter flagged the Gulf Coast Ammonia deal's leverage step-up (pro forma net debt/EBITDA to ~1.73x) as a modest offset to the cheaper multiple.
• Technical: the NOK 437-440 shelf (S1) is now a genuinely tested-and-reclaimed level, not just a shallow line — price closed below it for two straight weeks during the June low, then reclaimed and has held above it for three consecutive weeks since. A new near-term resistance band (~468-472) is worth watching as the first hurdle before R1 at 500.
• Catalysts / offsets: insider buying continued past last week's cutoff (CFO purchase July 20, following a Board Member's buy on the day of the Q2 print) — a mild bullish tell; Berenberg trimmed its target to NOK 440 (Hold) on July 22, while Pareto cut its own target to NOK 560 but reiterated its bullish call — net a wash on the analyst side; falling urea prices are a soft fundamental headwind on the normalized-earnings case the panel's DCF leans on.
• Verdict: WAIT (unchanged)

Nothing here moves the underlying math. The panel's normalized-earnings and DCF estimates still converge in the NOK 330-380 range, meaningfully below today's price, and the weekly trend remains below its ~557 reclaim level. What's genuinely new is that the support shelf just below current price has proven itself — a real structural signal — while the fundamental backdrop offers a mild positive (insider buying) and a mild negative (softer urea prices, a tighter analyst target) that roughly cancel out. Absent a decisive move in either direction, the panel stays parked.

Key levels

Key support at NOK 437-440 has upgraded from "shallow shelf" to tested-and-reclaimed — price closed below it for two weeks during the June decline, then reclaimed it and has held for three straight weeks since. A new near-term resistance band has emerged at NOK 468-472, the first hurdle before the NOK 500 level and the deeper NOK 555-559 trend-reclaim zone. The deeper historical accumulation zone at NOK 340-345 remains untested since the bounce began. Analyst consensus target sits around NOK 490, though third-party aggregators show wide dispersion (NOK 416-539) depending on sample and date.

What legendary investors think

We ran Yara past a panel of six legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Is a proven, tested support level combined with quiet insider buying enough to call this stock's stabilization real, or does a weekly trend still stuck below its reclaim level and a valuation gap that hasn't closed mean the more favorable price still hasn't arrived?

The numbers

Metric	Value
Price / Market cap	NOK 456.1 / ~NOK 116B
P/E (TTM / fwd)	~7.66x / ~8.09x — cheaper than last week's 8.6x/10.7x despite a higher price, on the Q2 earnings beat
ROE	~14.6%-17.9% depending on source (GuruFocus / stockanalysis.com, Jul 2026) — same reconciliation caveat as prior week applies
Operating margin	~18% EBITDA margin (FY2025); Q2 2026 EBITDA USD 906M vs USD 652M a year prior
Dividend yield	~4.83%
Debt / equity	Net debt/EBITDA ~1.0x pre-acquisition / ~1.73x pro forma (Gulf Coast Ammonia, $1.3B); net debt-to-equity ~0.33x — both inside policy
Free cash flow	Q2 2026 FCF USD 583M (USD 777M pre-financing); medium-term target >$600M cumulative FCF expansion and >$350M EBITDA improvement by 2030

Figures as of 2026-07-24/25; sourced from stockanalysis.com, StreetInsider (Berenberg target cut, Jul 22), MarketScreener (Pareto target cut), Yara corporate releases (insider trades, Jul 17 & Jul 20), Quartr's Q2 2026 summary, and GuruFocus. Multiple third-party aggregators show wide dispersion on P/E/ROE for this name — the figures above are reconciled across sources rather than taken from one. Next print: Q3 2026 results, expected October 2026.

The bottom line

With Q3 not due until October, the near-term case still rests on price action rather than a fresh data point — and this week's action was closer to a pause than a move. A weekly close above the new 468-472 resistance band, and then above NOK 500, would be the first technical evidence the trend itself is turning, independent of valuation; a close back above NOK 555-559 remains the level the panel treats as full trend confirmation. Conversely, a slide back toward NOK 340-345 would bring price into the range where the panel's normalized-earnings and DCF estimates already sit, letting the low-multiple case gain valuation backing rather than resting on the multiple alone. Absent either move, expect the panel to stay parked at Neutral across the board into the next print.

The panel's take

Verdict: WAIT · Conviction: MED · Last price: 446.7

What changed since 2026-07-25:

• Price: 456.1 → 446.7 (-2.06%)
• Panel: 0 of 6 → 2 of 7 now Bullish — composition also changed: added The Disruptive-Innovation Seeker, The Forensic Skeptic, The GARP Operator; removed The Macro Opportunist, The Quality Rationalist
• Trigger: BUY trigger: a weekly close above the 20-week EMA at 469.15, confirming the correction is over and the monthly Stage 2 uptrend has resumed. Alternatively, a deep pullback toward 403–406 (monthly 61.8% Fib / weekly 78.6% Fib), a historical accumulation zone where the setup becomes asymmetric with downside historically contained near 400. SELL trigger: a monthly close below the 20-month EMA at 422.42, breaking the Stage 2 uptrend and signaling a shift to Stage 3/4.
• Verdict: WAIT (unchanged)

Since the prior article (July 25, price 456.1), the stock has drifted slightly lower into the weekly correction, and the panel composition shifted with three new voices joining. The key change is not the modest price decline but a crystallization of the debate: the prior panel had no bulls at all, while this panel now has two clear bulls (The Asymmetric Bargainer, The Forensic Skeptic) who argue the data supports buying at these levels — yet the WAIT verdict holds because four of five cautious voices still object on price/timing, and the new Intrinsic-Value Modeler's through-the-cycle fair value of NOK 465 suggests the stock isn't even cheap yet, muting the urgency to act.

This is a BUY vs WAIT split, not BUY vs SELL. The bulls (The Asymmetric Bargainer, The Forensic Skeptic, fundamental scout) all like the business deeply; the cautious camp (The Moat Compounder, The GARP Operator, The Intrinsic-Value Modeler, The Margin-of-Safety Hunter, technical scout) predominantly objects on price/timing — they want confirmation that the weekly correction is over or a deeper discount. The Disruptive-Innovation Seeker is the lone genuine business-objector (cyclical/no-exponential-growth), but her objection is ideological, not credit-risk-based. The structure says WAIT: great business, wrong entry.

Key levels

What legendary investors think

We ran Yara International ASA past a panel of 7 legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Are Yara's current earnings the beginning of a durable recovery supported by CBAM and structural ammonia-market shifts — or are they a cyclical peak inflated by the Hormuz disruption and about to mean-revert, making today's 7.58x P/E a trap rather than a bargain?

The bottom line

The weekly 20-week EMA at 469.15 is the level the panel is watching — a close above it would be the first concrete signal that the correction is exhausted and the monthly Stage 2 uptrend has resumed, at which point the bulls' deep-value thesis becomes actionable. On the downside, the monthly 20-month EMA at 422.42 is the structural line in the sand: a monthly close below it would break the Stage 2 uptrend and shift the entire framework to a Stage 3/4 distribution pattern, likely opening a path to the 403–406 zone (monthly 61.8% Fib / weekly 78.6% Fib), a historical accumulation zone where the setup becomes asymmetric for the cautious camp. The Q2 2026 earnings report on July 17 will be the next fundamental catalyst — if it shows nitrogen margins persisting above historical averages and management signals durability rather than a Hormuz unwind, expect the bulls to gain converts. If instead it shows margin compression toward the 8–9% range, the GARP Operator's cyclical-peak warning becomes the dominant thesis.

The panel's take

Verdict: WAIT · Conviction: MED · Last price: 416.2

What changed since 2026-08-01:

• Price: 446.7 → 416.2 (-6.83%)
• Panel: 2 of 7 → 4 of 7 now Bullish — composition also changed: added The Structural Tailwind Rider; removed The Disruptive-Innovation Seeker
• Trigger: BUY on (a) a weekly close above 454.02 (Volume POC) confirming the breakdown was a shakeout, or (b) a washout to 353–360 with a bullish reversal pattern. SELL if monthly closes below 413.10 confirming Stage 4, but even then entry merely shifts lower to 322–353.
• Verdict: WAIT (unchanged)

A month ago the panel was deadlocked at WAIT with the stock at 446.7. Since then, price has dropped 6.8%, right to the monthly EMA50 at 413, a level three cautious voices had flagged as the make-or-break line. The business itself hasn't weakened: Q2 delivered the best quarterly EBITDA in a decade, and management confirmed demand is resurging. But the price decline on excellent news is exactly what three cautious archetypes were waiting to see, and the bullish contingent now has a concrete support test to watch rather than a hypothetical one. The verdict stays WAIT because price still hasn't resolved: it's hovering at the trigger, not through it.

BUY vs WAIT split, not BUY vs SELL. Five bullish voices (fundamental-scout, The Asymmetric Bargainer, The GARP Operator, The Moat Compounder, The Structural Tailwind Rider) want to buy the business, but three of them flag the 413 support test as the gating factor. Of three cautious voices, The Intrinsic-Value Modeler and The Forensic Skeptic explicitly object on PRICE/TIMING: they like the business at lower levels (353–360) or on a reclaim of 454. Only The Margin-of-Safety Hunter objects on BUSINESS grounds (cyclical instability, defensive-investor disqualification). The structure is simple: great business, questionable entry. Price is the single blocker. An identifiable trigger exists, the monthly EMA50 test at 413, with a specific lower entry zone at 353–360 or a reclamation trigger at 454. This is a textbook WAIT.

Key levels

What legendary investors think

We ran Yara International ASA past a panel of 7 legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Does the undisputed quality of Yara's ammonia logistics moat and recovering fertilizer cycle justify buying at 416 with the stock sitting 1% above the monthly EMA50, or is the asymmetry math too thin until either the 454 resistance is reclaimed or the stock washes out to the 353–360 accumulation zone?

The bottom line

• Trigger to confirm the breakout: A weekly close above 454.02 (the volume POC) with expanding volume would invalidate the Stage 4 thesis and confirm the breakdown was a shakeout, opening the path to analyst targets at 515+.
• The line in the sand: A monthly close below 413.10 (monthly EMA50 / weekly EMA200 confluence) would confirm a Stage 4 transition and shift the buy zone down to the 353–360 washout area, where margin of safety exceeds 28%.
• Next catalyst: Q3 2026 results, with urea prices reportedly having rebounded from ~$410 to $500+/ton since Q2, will reveal whether the demand resurgence management flagged is sustaining or stalling.
• Risk to monitor: A sustained European gas price spike above $50/MMBtu would compress Yara's European production margins and test whether the ammonia arbitrage network truly decouples earnings from regional energy costs.

The panel's take

Verdict: SELL · Conviction: HIGH · Last price: 418.3 · Changed from WAIT

What changed since 2026-08-08:

• Price: 416.2 → 418.3 (+0.50%)
• Panel: 4 of 7 → 0 of 5 now Bullish — composition also changed: added none; removed The Moat Compounder, The Structural Tailwind Rider
• Trigger: A weekly close above 440.80 NOK (monthly 50% Fib, breaking the lower-highs sequence) combined with either (a) analyst estimate revisions turning positive, or (b) sustained urea prices above $500/tonne with demand recovery in Q3 delivery volumes. Alternatively, a decline to 350-380 NOK where normalized earnings provide a genuine The Margin-of-Safety Hunter/The Intrinsic-Value Modeler margin of safety would shift consensus to BUY on valuation grounds.
• Verdict: WAIT → SELL

A week ago the panel carried four bullish voices alongside three cautious ones, producing a WAIT verdict. Since then the two explicitly bullish archetypes — The Moat Compounder and The Structural Tailwind Rider — dropped off, leaving a panel where not a single voice argues the stock is a buy at these levels. The business case itself deteriorated: Q2 deliveries fell 17%, Citi's downgrade gained traction, and the technical breakdown accelerated through the weekly moving averages. The shift from WAIT to SELL reflects not a small price move but a collapse of the bull camp — the panel now sees a cyclical peak with no buyer willing to defend the stock.

The split is not BUY vs WAIT — it is BUY vs genuine BUSINESS rejection. Six of seven voices (technical-scout, The Asymmetric Bargainer, The Forensic Skeptic, The GARP Operator, The Margin-of-Safety Hunter, plus fundamental-scout's WAIT) all conclude the business is at a cyclical peak with deteriorating prospects, not merely mispriced. The lone neutral voice (The Intrinsic-Value Modeler at fair value +7%) does not tip the scales against this dominant BUSINESS objection. With no bullish voice arguing the company is sound at today's price and four voices explicitly calling a SELL/AVOID, a BALANCED would misrepresent the depth of the bearish consensus. This is not a "great company, wrong price" — it is a cyclical commodity producer at peak earnings with technical breakdown accelerating, and the panel nearly unanimously rejects the business case.

Key levels

What legendary investors think

We ran Yara International ASA past a panel of 5 legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Is the market already pricing in a full earnings normalization at a P/E of 7.5x and EV/EBITDA of 4.3x, or are those multiples actually near fair value once peak EBITDA contracts by 30-40%, leaving no cushion at all?

The bottom line

• Breakdown to confirm: A weekly close below the 403-413 NOK support zone (monthly 61.8% Fib and weekly EMA200) would confirm Stage 4 and open the path toward 350-353 NOK.
• Level that flips the call: A weekly close above 440.80 NOK, breaking the sequence of lower highs, paired with analyst estimate revisions turning positive, would challenge the bearish consensus.
• Earnings to watch: Q3 2026 delivery volumes (due October 2026) will either validate the CEO's demand-recovery narrative or confirm that deferred demand is permanently lost.
• Valuation zone to revisit: If the stock reaches 350-380 NOK, normalized earnings would offer a genuine margin of safety and at least two archetypes on this panel would turn constructive.

The panel's take

Verdict: BALANCED · Conviction: MEDIUM · Last price: 450.1 · Changed from SELL

Panel: 1 Bullish · 2 Neutral · 2 Bearish → BALANCED

What changed since 2026-08-15:

• Price: 418.3 → 450.1 (+7.60%)
• Panel: 0 of 5 → 1 of 5 now Bullish — composition also changed: added The Quality Rationalist; removed The Asymmetric Bargainer
• Trigger: BUY on a weekly close above 476.40 (the weekly 50% Fib and EMA20 resistance band, breaking the corrective structure) with the weekly MACD histogram turning less negative for at least two consecutive weeks, confirming momentum stabilisation. SELL on a weekly close below 440.80 (monthly 50% Fib), which would break the confluent support and likely trigger a test of the 403-413 zone.
• Verdict: SELL → BALANCED

The prior SELL was predicated on a support-breakdown scenario that never materialized: price moved above 440.80 and held, taking the stock out of the washout zone. The upgrade to BALANCED reflects not an improving business but the bearish technical thesis losing its edge without a confirming breakdown, leaving the panel split on whether the urea rebound is durable enough to justify entry before the 476 resistance gives way.

The SELL trigger from the prior article (a weekly close above 440.80) has fired — price is now 450.1. But the move from 418.3 to 450.1 did not resolve the debate; it merely took the stock out of the washout zone and into the middle of the range. The two bulls (The Forensic Skeptic on value, the fundamental scout's BALANCED) argue the cyclical recovery is underway: urea prices above $500/t, demand resurfacing in August, forward P/E of 10x, and a 14.4% upside to the consensus target. The two bears (The GARP Operator and The Quality Rationalist) reject the business itself — commodity cyclical, returns below cost of capital, earnings already rolling over into FY26 — and see the technical correction as unresolved. The Intrinsic-Value Modeler and The Margin-of-Safety Hunter land neutral at the current price: fair value ~480 and the Margin-of-Safety Hunter Number ~514, neither offering enough margin of safety to override the bearish weekly momentum. The panel splits 1-2-2, landing at BALANCED: the prior SELL no longer holds because the support-breakdown scenario didn't materialise, but the recovery narrative is too fresh to justify BUY without a weekly close above 476 confirming the uptrend.

Key levels

Key support at 446-447 is the confluent weekly 61.8% Fib (447.37) and weekly EMA50 (446.02) — price closed just above it on the as-of date and it is the first line the bears must breach. Below that sits 440.80, the monthly 50% Fib and a high-volume price zone, which was the prior article's trigger: a breakdown there would signal a test of the major floor at 403-413 (monthly 61.8% Fib plus weekly EMA200). Key resistance at 460-476 is the weekly EMA20 (460.31) and the weekly 50% Fib (476.40) — this is the band price must close above to break the corrective structure. The hard ceiling remains 599.40, the all-time high. The analyst consensus target of 515.10 sits above the immediate resistance and implies 14.4% upside.

What legendary investors think

We ran Yara International ASA past a panel of 5 legendary investors' frameworks.

Where they agree — and where they clash

The question it comes down to: Has the urea price recovery from $410 to above $500/t marked the start of a durable earnings upcycle, or is it a mean-reversion bounce within a structurally oversupplied industry that will fade as European gas costs compress margins into FY26?

The bottom line

• Trigger to confirm the breakout: A weekly close above 476.40 with the MACD histogram turning less negative for at least two consecutive weeks would break the corrective weekly structure and confirm the uptrend.
• Risk to monitor: A weekly close below 440.80 would break confluent monthly support and likely open a test of the 403 to 413 accumulation zone.
• Next catalyst: Q3 2026 earnings around late October. If the August demand rebound translates into an EPS beat with upward guidance, the recovery narrative gains the evidence it currently lacks.
• Further out: Sustained urea above $500/t through the September to October application season paired with European gas below TTF €40 would confirm the margin expansion that both The Intrinsic-Value Modeler and The Quality Rationalist need to raise their estimates.